# EDGAR Filing Document

**Accession Number:** 0001145604
**File Stem:** 0001826466-23-000012
**Filing Date:** 2023-3
**Character Count:** 7467
**Document Hash:** 7d79468282f78eba2368172c4373823b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001826466-23-000012.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001826466-23-000012

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**EFFECTIVENESS DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NIKA PHARMACEUTICALS, INC
- **CENTRAL INDEX KEY:** 0001145604
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS TRANSPORTATION EQUIPMENT [3790]
- **IRS NUMBER:** 900292940
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56234
- **FILM NUMBER:** 23787270

**BUSINESS ADDRESS:**
- **STREET 1:** 2269 MERRIMACK VALLEY AVENUE
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89044
- **BUSINESS PHONE:** 7023263615

**MAIL ADDRESS:**
- **STREET 1:** 2269 MERRIMACK VALLEY AVENUE
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89044

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTENNIAL GROWTH EQUITIES INC
- **DATE OF NAME CHANGE:** 20010724

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**UNITED STATES** | OMB APPROVAL |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**SECURITIES AND EXCHANGE COMMISSION** | OMB Number: 3235-0058 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Washington, D.C. 20549** |  |
|  | SEC FILE NUMBER |
|  | 000-56234 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**FORM 12b-25** | CUSIPNUMBER |
|  | 46020A 106 |

---

**NOTIFICATION OF LATE FILING**

*(Check One):* ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

---

| | |
|:---|:---|
| For Period Ended: **<u>December 31, 2022</u>**___________ | For Period Ended: **<u>December 31, 2022</u>**___________ |
| ☐ | Transition Report on Form 10-K |
| ☐ | Transition Report on Form 20-F |
| ☐ | Transition Report on Form 11-K |
| ☐ | Transition Report on Form 10-Q |
| ☐ | For the Transition Period Ended: |
| For the Transition Period Ended_________________________ | For the Transition Period Ended_________________________ |

---

---

| |
|:---|
| *Read Instruction (on back page) Before Preparing Form. Please Print or Type* |
| **Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.** |

---

If the notiﬁcation relates to a portion of the ﬁling checked above, identify the Item(s) to which the notiﬁcation relates:

---

| |
|:---|
| **PART I — REGISTRANT INFORMATION** |
| Nika Pharmaceuticals, Inc. |
| Full Name of Registrant |
| Centennial Growth Equities, Inc. |
| Former Name if Applicable |
| 2269 Merrimack Valley Avenue |
| Address of Principal Executive Office (Street and Number) |
| Henderson, NV 89044 |
| City, State and Zip Code |

---

**PART II — RULES 12b-25(b) AND (c)** 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

---

| | | |
|:---|:---|:---|
| ☒ | (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| ☒ |  |  |
| ☒ | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| ☒ |  |  |
| ☒ | (c) | The accountant'statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

---

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

------

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be ﬁled within the prescribed time period.

The Company is unable to file, without unreasonable effort or expense, its Form 10-K for the year ended December 31, 2022. Additional time is needed for the Company to compile and analyze supporting documentation in order to complete the Form 10-K and in order to permit the Company's independent registered public accounting firm time to complete its review of the financial statements included in the Form 10-K. The Company intends to file the Form 10-K as soon as possible.

**PART IV — OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard
to this notification

<u>Clifford Redekop </u> <u>702 </u> <u>326-3615 </u> <br> (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13
 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
 Investment Company Act of 1940 during the preceding 12 months or for such
 shorter period that the registrant was required to file such report(s)
 been filed? If answer is no, identify report(s). <br>
 Yes
 ☒ No ☐

(3) Is it anticipated that any significant change in results
 of operations from the corresponding period for the last fiscal year will
 be reflected by the earnings statements to be included in the subject
 report or portion thereof? <br>
 Yes ☐ No
 ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

---

| |
|:---|
| Nika Pharmaceuticals, Inc. |
| (Name of Registrant as Specified in Charter) |

---

has caused this notiﬁcation to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date | March 31, 2023 | By *<u>/S/</u><u>Dimitar Savov</u>* |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dimitar Savov |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer |

---

------